Aspen Pharmacare posted a 5% rise in half-year earnings on Monday and said it expects double-digit revenue and core profit ...

It's the second year in a row that Lilly has used the Oscars as a platform to drive home a message about GLP-1-based obesity ...

Over 30 state attorneys general including in Indiana, Kentucky, and Ohio have urged the Federal Food and Drug Administration ...

More than a third of food-allergic kids were able to eat full servings of their trigger foods after treatment with an ...

AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...

HHS Secretary Robert F. Kennedy Jr. is proposing to strip public participation from much of the business his agency conducts ...

Drugmaker AbbVie has agreed to license a weight-loss drug currently in development from Gubra for up to about $2.2 billion, marking its entry into the obesity treatment market.

California made a bold announcement that it would manufacture a state-branded, low-cost insulin. It still is not here.

Why it matters: More than 3.5 million Californians have diabetes, and insulin is a life-saving part of their disease ...

The lifetime risk of dementia after age 55 is about 42%, according to a recent study published in the journal Nature Medicine. Around 1 million adults in the U.S. are projected to develop dementia ...

Rosacea treatment is a marathon — not a sprint — and there’s a need for increased emphasis on a patient-centric approach to ...